Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PORTER: Immunotherapy Combinations in Metastatic Castration-resistant Prostate Cancer
NCT03835533Phase 1Completed
- Sponsor
- Parker Institute for Cancer Immunotherapy
- Start
- Jun 2019
- Primary completion
- Oct 2022
- Modality
- Antisense DNA, Prophylactic Vaccines, Small Interfering RNA (siRNA)
- Countries
- 1
01
Overview
Phase 1, open-label trial of nivolumab, bempegaldesleukin, Flt3 ligand, poly iclc and INO-5151 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Parker Institute for Cancer Immunotherapy. Started Jun 2019; status: completed.
02
Drugs
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03835533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03835533.